Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 8, 2012, Pages 737-745

  Zhao, Liang Yun ^a   Mao, Xiao Peng ^a   Chao, Kai Yuan ^b   Guo, Sheng Jie ^a   Qiu, Shao Peng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

In vitro; Osseous metastasis; Prostate carcinoma; Prostate specific membrane antigen

Indexed keywords

GELATINASE B; MESSENGER RNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VASCULOTROPIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE LESION; BONE METASTASIS; BONE TISSUE; CANCER CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; SCLEROSIS; WESTERN BLOTTING;

ANIMALIA; MUS;

EID: 84864685916     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500085     Document Type: Article

References (37)

1. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009; 48: 193-199.
2. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50: 472-483.
3. Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol 2004; 19: 715-718.
4. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61: 554-571.
5. Zhang L, Wang CY, Yang R, Shi J, Fu R, Chen L, et al. Real time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 2008; 26: 634-640.
6. Ikegami S, Tadakuma T, Ono T, Suzuki S, Yoshimura I, Asano T, et al. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 2004; 95: 367-370.
7. Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, et al. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol 2009; 27: 26-32.
8. Zhao W, Xu Y, Kong D, Liu R, Zhang Z, Jin C, et al. Tissueselective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. Urol Oncol 2009; 27: 539-547.
9. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26: 5310-5324.
10. Wang W, Tavora F, Sharma R, Eisenberger M, Netto GJ. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol 2009; 27: 525-528.
11. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev 2007; 33: 230-283.
12. Barwe SP, Maul RS, Christiansen JJ, Anilkumar G, Cooper CR, Kohn DB, et al. Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol 2007; 30: 899-904.
13. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostatespecific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005; 288: C975-C981.
14. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40: 1754-1761.
15. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539.
16. Ghosh A, Wang X, Klein E, Heston WD. Novel role of prostatespecific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005; 65: 727-731.
17. Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003; S75-S85.
18. Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ, et al. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 2007; 67: 1791-1800.
19. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007; 144: 1361-1372.
20. Thomas AG, Wozniak KM, Tsukamoto T, Calvin D, Wu Y, Rojas C, et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006; 576: 327-337.
21. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003; 54: 249-257.
22. Reichert JC, Quent VM, Burke LJ, Stansfield SH, Clements JA, Hutmacher DW. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials 2010; 31: 7928-7936.
23. Akimoto S, Furuya Y, Akakura K, Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J 1998; 45: 97-104.
24. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110-116.
25. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198.
26. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-573.
27. Qi L, Robinson WA, Brady BM, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003; 23: 3917-3922.
28. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
29. Ehrenfried JA, Ko TC, Thompson EA, Evers BM. Cell cyclemediated regulation of hepatic regeneration. Surgery 1997; 122: 927-935.
30. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001; 58: 132-139.
31. Chen J, De S, Brainard J, Byzova TV. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes 2004; 11: 1-11.
32. Walsh K, Sriprasad S, Hopster D, Codd J, Mulvin D. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer Prostatic Dis 2002; 5: 119-122.
33. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
34. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
35. Britton KE, Feneley MR, Jan H, Chengazi VU, Granowska M. Prostate cancer: the contribution of nuclear medicine. BJU Int 2000; 86 (Suppl 1): 135-142.
36. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix met alloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365-5369.
37. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix met alloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998; 152: 591-596.